1,454 results on '"Bladé, Joan"'
Search Results
2. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
3. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
4. Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas
5. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
6. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
7. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease
8. Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution
9. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis
10. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
11. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
12. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis
13. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma
14. Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma
15. Multiple Myeloma
16. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
17. Extramedullary disease in multiple myeloma: a systematic literature review
18. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
19. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
20. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
21. A case of benign immunoglobulin D monoclonal gammopathy of undetermined significance with 26 years of follow‐up
22. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
23. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
24. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses
25. Plasma Cell Leukemia and Extramedullary Plasmacytoma
26. Solitary Plasmacytomas and Soft-Tissue Involvement in Multiple Myeloma
27. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
28. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
29. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
30. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
31. The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma.
32. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma
33. Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
34. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
35. Outcomes of Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma According to Clinical Trials Enrollment: Experience of a Single Institution
36. OA-12 Predictors of unsustained measurable residual disease (MRD) negativity in transplant-eligible multiple myeloma (MM) patients
37. OA-20 Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial
38. P-045 Early treatment with bispecific T-cell redirectors (teclistamab or talquetamab) + daratumumab in newly diagnosed high-risk multiple myeloma: an open-label, phase 2, pilot study (GEM-TECTAL)
39. P-367 High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience
40. P-311 Survival of patients with relapsed/refractory multiple myeloma receiving palliative therapy with cyclophosphamide/ prednisone: results in 346 patients from a single institution over the last 50 years
41. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p
42. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
43. Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis
44. Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation
45. Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
46. Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis
47. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
48. The renal range of the κ/λ sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease
49. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
50. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.